Brain+ ApS (BRAINP) - Total Liabilities
Based on the latest financial reports, Brain+ ApS (BRAINP) has total liabilities worth Dkr20.90 Million DKK (≈ $3.27 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash flow conversion of Brain+ ApS to assess how effectively this company generates cash.
Brain+ ApS - Total Liabilities Trend (2015–2024)
This chart illustrates how Brain+ ApS's total liabilities have evolved over time, based on quarterly financial data. See shareholders equity of Brain+ ApS for net asset value and shareholders' equity analysis.
Brain+ ApS Competitors by Total Liabilities
The table below lists competitors of Brain+ ApS ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Octopus Aim VCT 2 PLC
LSE:OSEC
|
UK | GBX367.00K |
|
Norrland Gold Corp
V:NORR
|
Canada | CA$27.84K |
|
National World PLC
LSE:NWOR
|
UK | GBX22.70 Million |
|
Vivanco Gruppe AG
F:VG0K
|
Germany | €23.05 Million |
|
Colefax Group
LSE:CFX
|
UK | GBX42.80 Million |
|
Ondine Biomedical Inc
LSE:OBI
|
UK | GBX5.95 Million |
Liability Composition Analysis (2015–2024)
This chart breaks down Brain+ ApS's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see BRAINP market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.80 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.45 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.59 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Brain+ ApS's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Brain+ ApS (2015–2024)
The table below shows the annual total liabilities of Brain+ ApS from 2015 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Dkr22.15 Million ≈ $3.47 Million |
-6.08% |
| 2023-12-31 | Dkr23.59 Million ≈ $3.69 Million |
-18.64% |
| 2022-12-31 | Dkr28.99 Million ≈ $4.54 Million |
+10.31% |
| 2021-12-31 | Dkr26.28 Million ≈ $4.11 Million |
-6.05% |
| 2020-12-31 | Dkr27.97 Million ≈ $4.38 Million |
+35.70% |
| 2019-12-31 | Dkr20.61 Million ≈ $3.23 Million |
+24.67% |
| 2018-12-31 | Dkr16.53 Million ≈ $2.59 Million |
+73.13% |
| 2017-12-31 | Dkr9.55 Million ≈ $1.49 Million |
+88.51% |
| 2016-12-31 | Dkr5.07 Million ≈ $792.61K |
+91.33% |
| 2015-12-31 | Dkr2.65 Million ≈ $414.27K |
-- |
About Brain+ ApS
Brain+ A/S, a healthtech company, develops and commercializes technology solutions in dementia care primarily for cognitive stimulation therapy. The company is developing Ayla, a scalable dementia care platform that offers practical, human-centered, and clinically proven software-based dementia therapy and care solutions. It is also developing Ayla " your CST Assistant, a software-based dementia … Read more